{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:13:49Z","timestamp":1779923629652,"version":"3.53.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sofosbuvir (SOF), a nucleotide inhibitor of the hepatitis C virus (HCV) polymerase, is a component of several all-oral HCV therapies. GS-331007, SOF\u2019s predominant metabolite, is renally eliminated and accumulates 5- to 20-fold in patients with advanced chronic kidney disease (CKD) or undergoing hemodialysis (HD), respectively. Preclinical data did not determine whether these exposures represented a risk for toxicity. Therefore subjects with advanced CKD were not included in registrational studies and SOF was not initially approved for use in advanced CKD. Nevertheless, after initial licensing, off-label use of SOF at full or reduced doses was reported in patients with kidney disease. Two clinical trials of SOF-containing therapies were conducted in patients with end-stage kidney disease, demonstrating safety and efficacy. These led to expanded US Food and Drug Administration approval in 2019 for the use of SOF-containing regimens in patients with advanced CKD, including dialysis dependence. Even so, given the availability of protease inhibitor\u2013containing direct-acting antiviral regimens, there was a reluctance by some practitioners to use SOF-containing regimens in moderate to severe kidney disease. Here we review the existing data on SOF\u2019s pharmacokinetics, toxicology, efficacy and safety in patients with kidney disease. Data from both clinical trials and real-world practice settings indicate that in patients with moderate to severe kidney disease, full-dose SOF-based regimens have high rates of efficacy and acceptable safety and tolerability profiles, without increased risk for cardiac adverse events or clinically meaningful changes in kidney function. SOF-based regimens are safe and effective in patients who have moderate to severe kidney disease, including those undergoing HD.<\/jats:p>","DOI":"10.1093\/ndt\/gfab072","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T14:20:59Z","timestamp":1618237259000},"page":"2327-2334","source":"Crossref","is-referenced-by-count":11,"title":["Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease"],"prefix":"10.1093","volume":"37","author":[{"given":"Meghan E","family":"Sise","sequence":"first","affiliation":[{"name":"Depertment of Medicine, Massachusetts General Hospital , Harvard University, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McQuaid","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City , CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami , Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"2022112304492649800_gfab072-B1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12916-017-0815-7","article-title":"Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals","volume":"15","author":"Baumert","year":"2017","journal-title":"BMC Med"},{"key":"2022112304492649800_gfab072-B3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B4","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2022112304492649800_gfab072-B5","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41598-018-36437-6","article-title":"Association of hepatitis C and B virus infection with CKD and impact of hepatitis C treatment on CKD","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci Rep"},{"key":"2022112304492649800_gfab072-B6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2369-14-187","article-title":"Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Nephrol"},{"key":"2022112304492649800_gfab072-B7","doi-asserted-by":"crossref","first-page":"e100790","DOI":"10.1371\/journal.pone.0100790","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"2022112304492649800_gfab072-B8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"key":"2022112304492649800_gfab072-B9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jvh.12413","article-title":"A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection","volume":"22","author":"Park","year":"2015","journal-title":"J Viral Hepat"},{"key":"2022112304492649800_gfab072-B10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.29505","article-title":"Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD","volume":"67","author":"Park","year":"2018","journal-title":"Hepatology"},{"key":"2022112304492649800_gfab072-B11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J Viral Hepat"},{"key":"2022112304492649800_gfab072-B12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022112304492649800_gfab072-B13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","article-title":"Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease","volume":"97","author":"Sise","year":"2020","journal-title":"Kidney Int"},{"key":"2022112304492649800_gfab072-B14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"2022112304492649800_gfab072-B15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03710708","article-title":"Hepatitis C infection and chronic renal diseases","volume":"4","author":"Perico","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022112304492649800_gfab072-B16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"2022112304492649800_gfab072-B17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jvh.12276","article-title":"Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat"},{"key":"2022112304492649800_gfab072-B18","author":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America"},{"key":"2022112304492649800_gfab072-B19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14656566.2014.857656","article-title":"Sofosbuvir for the treatment of hepatitis C virus","volume":"15","author":"Asselah","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2022112304492649800_gfab072-B21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2022112304492649800_gfab072-B23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ajg.2015.391","article-title":"Harvoni (ledipasvir with sofosbuvir)-induced renal injury","volume":"111","author":"Wanchoo","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2022112304492649800_gfab072-B24","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.14309\/crj.2017.84","article-title":"Acute interstitial nephritis associated with sofosbuvir and daclatasvir","volume":"4","author":"Ashraf","year":"2017","journal-title":"ACG Case Rep J"},{"key":"2022112304492649800_gfab072-B25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"2022112304492649800_gfab072-B26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int"},{"key":"2022112304492649800_gfab072-B27","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"2022112304492649800_gfab072-B28","author":"U.S. Food & Drug Administration","year":"10 2021,"},{"key":"2022112304492649800_gfab072-B29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12799","article-title":"DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting","volume":"29","author":"Beinhardt","year":"2016","journal-title":"Transpl Int"},{"key":"2022112304492649800_gfab072-B30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B31","first-page":"2065","article-title":"Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure","volume":"32","author":"Dumortier","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2022112304492649800_gfab072-B32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/23744235.2015.1078908","article-title":"Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency","volume":"47","author":"Hundemer","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"2022112304492649800_gfab072-B33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"2022112304492649800_gfab072-B34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR &lt;30 ml\/min","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int"},{"key":"2022112304492649800_gfab072-B35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ekir.2017.04.003","article-title":"Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen","volume":"2","author":"Agarwal","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2022112304492649800_gfab072-B36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/hep4.1035","article-title":"Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction","volume":"1","author":"Cox-North","year":"2017","journal-title":"Hepatol Commun"},{"key":"2022112304492649800_gfab072-B37","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/jvh.12983","article-title":"Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency","volume":"25","author":"Singh","year":"2018","journal-title":"J Viral Hepat"},{"key":"2022112304492649800_gfab072-B38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112304492649800_gfab072-B39","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"key":"2022112304492649800_gfab072-B40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.11.018","article-title":"Sofosbuvir (GS-7977) plus peginterferon\/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial","volume":"58","author":"Rodriguez-Torres","year":"2013","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B41","author":"Center for Drug Evaluation and Research"},{"key":"2022112304492649800_gfab072-B42","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/S0168-8278(12)61113-1","article-title":"The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977 [abstract no. 1101]","volume":"56","author":"Cornpropst","year":"2012","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2022112304492649800_gfab072-B45","doi-asserted-by":"crossref","first-page":"e1003030","DOI":"10.1371\/journal.ppat.1003030","article-title":"Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides","volume":"8","author":"Arnold","year":"2012","journal-title":"PLoS Pathog"},{"key":"2022112304492649800_gfab072-B46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","article-title":"Sofosbuvir, a significant paradigm change in HCV treatment","volume":"3","author":"McQuaid","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"2022112304492649800_gfab072-B47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.27488","article-title":"Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C","volume":"62","author":"Ahmad","year":"2015","journal-title":"Hepatology"},{"key":"2022112304492649800_gfab072-B48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0960327115592939","article-title":"Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys","volume":"35","author":"Luo","year":"2016","journal-title":"Hum Exp Toxicol"},{"key":"2022112304492649800_gfab072-B49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/hdi.12604","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: a prospective observational study","volume":"22","author":"Surendra","year":"2018","journal-title":"Hemodial Int"},{"key":"2022112304492649800_gfab072-B50","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1016\/S0618-8278(19)30419-0","article-title":"Ledipasvir\/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis","volume":"70","author":"Chuang","year":"2019","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B51","doi-asserted-by":"crossref","first-page":"S616","DOI":"10.1016\/S0168-8278(20)31699-8","article-title":"Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir","volume":"73","author":"Telep","year":"2020","journal-title":"J Hepatol"},{"key":"2022112304492649800_gfab072-B52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"key":"2022112304492649800_gfab072-B53","doi-asserted-by":"crossref","first-page":"14332","DOI":"10.1038\/s41598-020-71205-5","article-title":"Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis","volume":"10","author":"Shehadeh","year":"2020","journal-title":"Sci Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfab072\/37214833\/gfab072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/12\/2327\/47203085\/gfab072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/12\/2327\/47203085\/gfab072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:05:29Z","timestamp":1698883529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/12\/2327\/6225011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,4,12]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfab072","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2021,4,12]]}}}